#
In Your Own Words
Jun 3, 2020
In celebration of World FSHD Day and in support of the upcoming Voice of the Patient Forum, Molly White of Dyne Therapeutics invites anyone living with FSHD to describe what would be a meaningful benefit from a successful therapy.
#
Progress Update: Regulation and activity of the DUX4 transcription factor
May 20, 2020
Dr. Tapscott provides an update on his multi-year grant.
#
Progress Update: Antisense Oligonucleotide – Antibody Conjugates to Treat FSHD
May 20, 2020
Dr. Marusak provides an update on progress so far.
#
Dyne Therapeutics Accelerates Programs in FSHD
May 19, 2020
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
Fulcrum Therapeutics Update on ReDUX4 Study
May 13, 2020
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.
#
A Message of Hope and Perseverance from Chris Carrino
Apr 26, 2020
Those living with FSHD know firsthand what it's like to see the world through a changing lens. Recently, Chris Carrino shared some words of encouragement on the Brooklyn Nets website and social media outlets.
#
Progress Update: Base editing of DUX4 somatic polyadenylation signal
Apr 17, 2020
Darina Šikrová provides a progress update of her work on using a novel genome editing tool to target DUX4.
#
Losmapimod for FSHD Program Update
Apr 2, 2020
As a result of the suspension of clinical-trial activity by a number of the Company’s clinical trial sites stemming from the pandemic, the Company is currently assessing the impact to the ReDUX4 clinical trial.
#
GiveBIG 2020
Mar 26, 2020
GiveBIG for Seattle. Friends of FSH Research is suggesting you donate to other non-profits for GiveBIG this year.
#
Progress Update: In vivo model to validate drugs targeting DUX4 enhancer/promoter activity
Mar 10, 2020
Latest progress from Yosuke Hiramuki.
#
Call for Proposals
Feb 7, 2020
Our latest call for research proposals.
#
Progress Update: Travel Reimbursement for Clinical Study Participants
Feb 3, 2020
Dr. Kyba provides a brief update on our help with recruiting study participants.
#
Molecular Mechanisms Slideshow
Feb 1, 2020
Slideshow on molecular mechanisms of DUX4 which was presented at the Wellstone Research Update 2020 by Danielle Hamm PhD.
#
Aberrant Translation Slideshow
Feb 1, 2020
Slideshow on aberrant translation which was presented at the Wellstone Research Update 2020 by Sujatha Jagannathan PhD.
#
Epigenetics Slideshow
Jan 31, 2020
Slideshow on epigenetics which was presented at the Wellstone Research Update 2020 by Peter Jones PhD.
#
Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in FSHD
Jan 30, 2020
Fulcrum Therapeutics announced that the FDA has granted Orphan Drug Designation to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.
#
Progress Update: DUX4 mRNA silencing using CRISPR-Cas13
Jan 28, 2020
Rashnonajad provides the initial progress update showing efficiently reduced DUX4 mRNA and consequently DUX4 protein in FSHD cells.
#
Voice of the Patient Forum for Drug Development
Jan 9, 2020
The Friends of FSH Research is partnering with the FSHD Society on a landmark Voice of the Patient Forum for Drug Development.
#
Participate in FSHD Research
Dec 15, 2019
Researchers at the University of Washington and Seattle Children’s Hospital are seeking volunteers for a study on FSHD.
#
Progress Update: Mechanisms of DUX4-Induced Muscle Atrophy
Dec 9, 2019
Sachiko Homma provides the final update on DUX4's apparent affect on muscle degradation.